By George Ongkojoyo 
A landmark study conducted by researchers at University College London (UCL) and the Francis Crick Institute has identified a critical link between systemic immune health and cancer prognosis, revealing that the concentration of immune cells in a patient’s blood is a far more potent predictor of survival than previously understood. Utilizing a groundbreaking computational tool known as ImmuneLENS (Immune Lymphocyte Estimation from Nucleotide Sequencing), the research team analyzed the genetic blueprints of over 90,000 individuals, uncovering that cancer patients with higher proportions of circulating T cells experience a 47% reduction in mortality over a five-year period following surgery. The findings, published in the journal Nature Genetics, represent a paradigm shift in oncology, moving the focus from the localized environment of the tumor to the broader, systemic immune response of the patient.
The Evolution of Genomic Diagnostics: Introducing ImmuneLENS
For decades, the primary focus of cancer immunology has been the "tumor microenvironment"—the immediate area surrounding a cancerous growth. While the presence of immune cells within a tumor is known to be a positive indicator, it offers only a localized snapshot of a complex, body-wide battle. The development of ImmuneLENS marks a significant technological leap by allowing scientists to extract detailed immunological data from Whole Genome Sequencing (WGS) for the first time.
Whole Genome Sequencing is a comprehensive laboratory process that determines the nearly complete DNA sequence of an individual’s genome. While WGS has been used extensively to identify genetic mutations that drive cancer, its utility in measuring the proportions of specific immune cells, such as T cells and B cells, remained untapped until now. ImmuneLENS addresses this gap by utilizing complex algorithms to calculate the ratio of these lymphocytes directly from blood-derived WGS data.
Dr. Robert Bentham, the study’s first author from the UCL Cancer Institute, described the methodology as a fundamental change in perspective. "Lots of approaches that measure immune cells from genetic data are like looking for a needle in a haystack," Bentham explained. "Our approach in this study instead looks at the haystack itself and asks how the presence of immune cells changes its overall shape. It’s a different, more efficient way of finding the needle."
Data Scale and the 100,000 Genomes Project
The sheer scale of the study was made possible through the 100,000 Genomes Project, a major UK health initiative managed by Genomics England in partnership with NHS England. This project has compiled one of the world’s largest repositories of genomic data, specifically targeting patients with rare diseases and various forms of cancer. By analyzing 90,000 samples from this cohort, the UCL and Francis Crick team were able to compare the immune profiles of cancer patients against those of healthy individuals with unprecedented statistical power.
The researchers observed a consistent trend: cancer patients generally possess a significantly lower proportion of circulating T cells than their healthy counterparts. This suggests that cancer does not just affect the organ in which it originates but exerts a disruptive influence on the entire immune system. The data indicated that this systemic disruption is a hallmark of the disease across a wide spectrum of cancer types, including lung, breast, and colorectal cancers.
T Cells as a Critical Marker for Survival
The most striking finding of the research is the correlation between T cell levels and long-term survival. T cells are the "soldiers" of the immune system, responsible for identifying and destroying cells that have become cancerous or infected. The study found that even when accounting for variables such as the patient’s age, the stage of the cancer, and the specific type of malignancy, the proportion of T cells in the blood remained a "strong predictor" of outcome.
Specifically, patients who maintained a higher level of these cells saw a 47% lower risk of death within five years of their surgical interventions. This finding suggests that a patient’s systemic "immune fitness" may be just as important as the clinical stage of their tumor. Professor Nicholas McGranahan, the senior author of the study and a prominent figure at the UCL Cancer Institute, noted that this systemic view might surpass the accuracy of traditional tumor-infiltrating lymphocyte (TIL) counts.
"What’s going on with immune cells in the blood seems to have a huge impact on cancer survival and may be able to predict how long a cancer patient will survive better than the number of T cells in the tumour alone," McGranahan stated. He emphasized that while previous research hinted at this connection, the ability to analyze it at such a massive scale is "game-changing" for the field of precision medicine.
B Cells and the Potential for Early Detection
Beyond T cells, the ImmuneLENS tool allowed for a sophisticated analysis of B cells—the lymphocytes responsible for producing antibodies. The researchers were able to distinguish between different types of B cells based on the antibodies they produce. One specific subset, B cells producing IgM/D antibodies, emerged as a key player. These cells are typically generated when the body first encounters a foreign antigen.
The study revealed that IgM/D-producing B cells were uniquely associated with improved survival outcomes. Furthermore, the researchers made a provocative discovery regarding early detection. Individuals who were healthy at the time of their blood draw but later developed cancer were found to have below-average levels of B cells in their system months or even years before their diagnosis.
This suggests that subtle, pre-cancerous changes in the immune system could serve as an early warning system. If integrated into routine screening, these biological markers could allow clinicians to identify high-risk individuals long before a physical tumor is detectable through imaging or biopsy.
Chronology of Development and Future Clinical Integration
The development of ImmuneLENS follows a logical progression of genomic research at UCL and the Francis Crick Institute.
- 2021: The research team released a predecessor tool designed to calculate T cell proportions from Whole Exome Sequencing (WES) data. While effective, WES only looks at the protein-coding regions of the genome (about 1-2% of total DNA).
- 2022-2023: The team refined the algorithm to work with Whole Genome Sequencing, which covers the entire genetic code, providing a much richer dataset for analysis.
- 2024: The publication of the current study in Nature Genetics confirms the efficacy of ImmuneLENS on a national scale using the 100,000 Genomes Project data.
- The Next Phase: Professor McGranahan’s team has recently been awarded a Biomarker Project Award from Cancer Research UK (CRUK). This funding is specifically designated to transition ImmuneLENS from a research tool into a clinical diagnostic test.
The integration into clinical practice is expected to be cost-effective. Because many cancer patients in the UK already undergo genomic testing as part of their standard care, the ImmuneLENS analysis could be performed on the existing data without requiring additional blood draws or expensive new laboratory equipment.
Demographic Insights and Immune Aging
The study also shed light on how cancer interacts with the natural aging process of the immune system. It is a well-documented biological fact that the immune system weakens as people age—a process known as immunosenescence. However, the researchers found that in cancer patients, this decline is significantly accelerated.
Interestingly, this "premature immune aging" was found to be more pronounced in male patients than in female patients. While the study did not definitively establish why this sexual dimorphism exists, it adds to a growing body of evidence suggesting that men and women may require different immunotherapeutic strategies. Understanding these differences is crucial for the development of personalized treatment plans that account for the biological sex of the patient.
Broader Implications for Medicine and Immunotherapy
The implications of this study extend far beyond cancer. By providing a tool to interrogate the "haystack" of genomic data for immunological signatures, ImmuneLENS could potentially be applied to other areas of medicine, such as autoimmune diseases, infectious diseases, and organ transplantation.
In the immediate context of oncology, the tool is expected to be particularly useful for predicting responses to immunotherapy. Immunotherapies, such as checkpoint inhibitors, work by "unmasking" cancer cells so the immune system can attack them. However, these treatments are only effective if the patient has a functional and sufficiently populated immune system to begin with. By measuring systemic T cell levels before starting treatment, doctors could better identify which patients are likely to benefit from these expensive and sometimes high-side-effect therapies.
Dr. Nisharnthi Duggan, Research Information Manager at Cancer Research UK, highlighted the importance of this data-driven approach. "We’re living in a golden age of research where we can use patient data in sophisticated ways to help us better understand cancer and how to beat it," she said. "Further research is needed, but this could one day become a tool to help doctors personalise treatment for people with cancer."
The research was supported by the TRACERx project (TRAcking Cancer Evolution through therapy/Rx), a multi-million-pound initiative aimed at understanding how lung cancer evolves over time and why it returns after treatment. As the medical community moves toward a more holistic view of the patient, the ability to measure the "health" of the immune system through a simple blood-based genomic test represents a significant stride toward more effective and personalized cancer care.
